BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
310 results:

  • 1. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
    Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
    Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
    Guo Y; Li S; Li C; Wang L; Ning W
    Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
    Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
    Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with her2 expression.
    Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
    J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study.
    Heredia A; Walbaum B; Vidal M; Itriago L; Camus M; Dominguez F; Manzor M; Martínez R; Murature G; Muñiz S; Navarro M; Guerra C; Merino T; Medina L; Ibañez C; Ramirez K; Acevedo F; Sánchez C
    Breast Cancer Res Treat; 2024 Jan; 203(1):173-179. PubMed ID: 37733187
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. her-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
    Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
    Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.
    Gorczyński A; Miszewski K; Gager Y; Koch S; Pötschke J; Ugrinovski D; Gabert J; Pospieszyńska A; Wydra D; Duchnowska R; Szymanowski B; Cierniak S; Kruecken I; Neumann K; Mirkov K; Biernat W; Czapiewski P
    Cancer Biomark; 2023; 38(1):17-26. PubMed ID: 37522200
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
    Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
    Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical Outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, her2, and PD-L1 Expression.
    Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
    Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast cancers.
    Santarosa M; Baldazzi D; Armellin M; Maestro R
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Distinct histological and clinical features associated with pure uterine serous carcinoma: A single institution experience.
    Zhi W; Zhan Y; He C; Jin Y
    Ann Diagn Pathol; 2023 Oct; 66():152173. PubMed ID: 37352704
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, ovarian cancer and Prostate cancer.
    Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. her2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
    Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
    Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Baicalein suppresses her2-mediated malignant transformation of her2-overexpressing ovarian cancer cells by downregulating her2 gene expression.
    Chuang TC; Fang GS; Hsu SC; Lee YJ; Shao WS; Wang V; Lee SL; Kao MC; Ou CC
    Environ Toxicol; 2023 Jul; 38(7):1609-1617. PubMed ID: 36988316
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Immunohistochemical markers of prognosis in adult granulosa cell tumors of the ovary - a review.
    Jung D; Almstedt K; Battista MJ; Seeger A; Jäkel J; Brenner W; Hasenburg A
    J Ovarian Res; 2023 Mar; 16(1):50. PubMed ID: 36869369
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The cancer Genome Atlas-like Prognostic Subgroups.
    Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
    Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Actin-like Protein 6A Expression Correlates with cancer Stem Cell-like Features and Poor prognosis in ovarian cancer.
    Chen PM; Wong CN; Wong CN; Chu PY
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768349
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
    Luen SJ; Viale G; Nik-Zainal S; Savas P; Kammler R; Dell'Orto P; Biasi O; Degasperi A; Brown LC; Láng I; MacGrogan G; Tondini C; Bellet M; Villa F; Bernardo A; Ciruelos E; Karlsson P; Neven P; Climent M; Müller B; Jochum W; Bonnefoi H; Martino S; Davidson NE; Geyer C; Chia SK; Ingle JN; Coleman R; Solbach C; Thürlimann B; Colleoni M; Coates AS; Goldhirsch A; Fleming GF; Francis PA; Speed TP; Regan MM; Loi S
    Ann Oncol; 2023 Apr; 34(4):397-409. PubMed ID: 36709040
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Cell-specific cargo delivery using synthetic bacterial spores.
    Kong M; D'Atri D; Bilotta MT; Johnson B; Updegrove TB; Gallardo DL; Machinandiarena F; Wu IL; Constantino MA; Hewitt SM; Tanner K; Fitzgerald DJ; Ramamurthi KS
    Cell Rep; 2023 Jan; 42(1):111955. PubMed ID: 36640333
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
    Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 16.